No Data
The opening ceremony of the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute.
The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute", established by the special zone government and fully owned, officially opened today (21st) at the Hong Kong Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Center" in Shenzhen Park also opened on the same day. The "one institute and one center" has become the first benchmark for the coordinated development of the "one zone and two parks" in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. Secretary for Administration and Home Affairs, Cheuk Wing-hing, stated that the National "14th Five-Year Plan" clearly supports Hong Kong in building an international innovation and technology center. The "Development Plan for Shenzhen Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone" also strongly supports the coordinated development of science and te
The Hang Seng Index rose by 41 points, Kingsoft surged quickly, while Xpeng retraced after its results.
nvidia (NVDA.US) rose nearly 5% before the earnings announcement, leading the Nasdaq to gain 195 points or 1% on the night of the 19th, while the Dow dropped 120 points or 0.3%. Hong Kong stocks fluctuated upward. The Hang Seng Index opened 40 points lower, initially dropped 87 points to 19,575 points, then rebounded, at one point rising 89 points to 19,752 points, ultimately closing up 41 points or 0.2% at 19,705 points; the national index rose 6 points or 0.1% to close at 7,090 points; the hang seng tech index rose 18 points or 0.4% to close at 4,413 points. The total trading volume of the market for the day was 114.671 billion yuan. Alibaba-W (09988.HK)
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
Guosheng Securities: The trend of the domestic innovative drugs industry is gradually shifting from license-in to license-out.
Against the backdrop of intense competition and saturation of innovative drug targets in the domestic market, going overseas is expected to break through the profit ceiling of the domestic market and align with the trend of globalizing the innovative drugs industry.
Lu Chongmao led a group to Dongguan to attend the Traditional Chinese Medicine Innovation and Development Conference, witnessing the signing of the cooperation agreement on talent cultivation.
Professor Lu Chongmao, Director of the Department of Health, led a delegation to Dongguan today (13th) to attend the 6th Greater Bay Area Traditional Chinese Medicine Inheritance and Innovation Development Conference, and tomorrow (14th) will witness the signing of the "Guangdong-Hong Kong Traditional Chinese Medicine Talent Training Cooperation Framework Agreement" between the Department of Health and the Guangdong Provincial Administration of Traditional Chinese Medicine, as well as the exchange of texts for multiple cooperation projects in the Greater Bay Area of Guangdong, Hong Kong, and Macao in traditional chinese medicine.
No Data
No Data